Thank you.
Good afternoon, Chairman McKinnon, Vice-Chairs Rempel Garner and Thériault, and members of the committee.
On behalf of Medicago, I would like to thank the committee for inviting us to participate today.
Medicago is a Canadian biopharmaceutical company with the mission to improve health outcomes by using its innovative plant-based technologies for rapid responses to emerging global health challenges.
Diseases know no boundaries. Medicago is working tirelessly to develop vaccines to help prevent disease, and to develop therapies to help treat those diseases.
Of course, no disease is more prevalent right now than COVID-19. We are proud to be contributing to the fight against COVID-19 by developing a made-in-Canada vaccine, which is currently in phase two clinical trials. Phase three is to be launched in the upcoming weeks.
We are proud to be a Canadian company based in Quebec City, and we make a significant contribution—